RTN4R and neoplasm: In the analysis of the therapeutic activity of tTF-NGR against A549 tumor xenografts, tumor growth was reduced by systemic i.v. application of tTF-NGR (n = 4 CD-1 nude mice) in comparison to the saline control group (n = 6 CD-1 nude mice; Fig 3B).